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Abstract 
 Objectives: This study explores the gender difference in patterns of drug use, risk behaviour, 
health and well-being among 934 new attenders at a Dublin syringe exchange. 
 
 Method: Over the period May 1997 to April 1998 data was collected by means of structured 
interviews with all clients who presented for the first time at Merchant’s Quay health promotion unit. 
All information collected was based on clients’ self-reported behaviour. 
 Results: Of the new clients, 24.3% were female and 75.7% were male. The female clients 
were significantly younger than their male counterparts (p<0.0001). The women were significantly 
more likely to report having a sexual partner who was an injecting drug user (OR 9.04, 95% CI, 5.9-
13.9) and to be living with an injecting drug user (OR 1.69, 95% CI, 1.2-2.3). They were also 
significantly more likely to share injecting equipment with their sexual partner (OR = 3.83, 95% CI, 
2.7-5.5) and to report recently sharing injecting paraphernalia (OR = 1.79, 95% CI, 1.3-2.5). However, 
the interval between initiating intravenous drug use and first presenting at the Merchant’s Quay health 
promotion unit was significantly shorter for female clients (p<0.0001). 
 Conclusions: One of the most important concerns with regard to illicit intravenous drug use is 
that of needle sharing, and the associated risks of infection with human immunodeficiency virus and 
hepatitis. This study highlights the greater personal involvement of women with other drug users, and 
its consequences in terms of health-related problems and risk behaviour. There is a need to address 
this issue, by taking advantage of the fact that women present for treatment at a younger age than their 
male counterparts and at a much earlier stage in their injecting career. 
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Introduction 
 Concern in Ireland and elsewhere with the spread of human immunodeficiency virus (HIV) 
led to a recognition that drug services need to be pro-active and not just react to the problems which 
drug use presents. The working philosophy which locates such interventions within a broad 
perspective on drug misuse and health has been termed ‘harm reduction’. Harm reduction emphasises 
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practical rather than idealised goals, by attempting to reduce the adverse consequences of drug use 
among those who continue to use drugs.1  
 The Merchant’s Quay Project rose to this challenge by offering a range of non-judgemental 
services accessible to drug users. In 1992 it expanded its service when it created a health promotion 
unit including needle exchanges. This unit, as the name suggests, is not intended as a single 
intervention (the exchange of injecting equipment). Rather it provides a range of services, all of which 
are considered essential aspects of promoting healthy behaviour among injecting drug users. The harm 
reduction philosophy has operated successfully in the Merchant’s Quay Project. Its ultimate objective 
is not only to reduce the consequences associated with engaging in risk behaviour, but to guide the 
individual gradually out of engagement in that problem behaviour.2 This paper examines the gender 
differences in drug use, risk behaviour, health and well-being of clients who present for the first time 
at Merchant’s Quay health promotion unit. Women are the focus of the study for a number of reasons. 
 Firstly, a significant minority of the new clients presenting at the health promotion unit were 
female. Secondly, there were notable gender differences in drug use patterns among the new attenders. 
Thirdly, to date there is no published Irish research which concentrates on gender differences in drug 
usage. Research undertaken in Ireland concerned with female injecting drug users has primarily 
concentrated on pregnant opiate users.1,4  
 Although the Merchant’s Quay Project conducted comprehensive research into the drug 
taking practices of male and female drug users over the period of one year, this paper only presents 
baseline data. Additionally, the focus for analysis is concerned with a number of core issues pertinent 
to female drugs users: younger and earlier presentation for treatment, more health-related problems, 
greater personal involvement with other drug users, and the resulting consequences in terms of risk 
behaviour. This paper makes no attempt to describe either all women who could be classified as drug 
users, or sub-groups of drug users within this population. Moreover, it does not suggest that female 
drug users are a homogenous group. 
Table 1: Drug using characteristics by gender (continuous variables) 
 
Gender  Male (n = 707) Female (n = 227) 
Variable 25% 75% 25% 75% pvalue 
Age at first contact 19 27 19 24 <0.001 
Age first drug use 15 22 16 21 <0.736 
Age first injected 18 24 17 22 <0.109 
Weeks smoking pre injecting 24 156 14 130 <0.057 
Weeks injecting pre attendance 16 156 9 104 <0.001 
 All the participants in this study were drug users who presented for the first time at the 
Merchant’s Quay health promotion unit between May 1, 1997 and April 30, 1998. Data were collected 
by means of a highly structured interview with all clients at the point of first contact. 
 In addition to basic information regarding demographic characteristics of clients, the 
interview schedule covered six major domains; drug treatment, current drug use, injecting risk 
behaviour, sexual risk behaviour, contact with medical services and health and well-being. All 
interviews were conducted in private by trained staff at the unit. 
 Confidentiality was assured, informed consent was obtained and all clients were guaranteed 
that refusal to partake in the interview would not jeopardise the service they would receive in the 
health promotion unit. All clients agreed at least in part to comply. The data obtained was based on the 
self-reported risk behaviour of respondents. It is possible that drug users may provide inaccurate 
information about their past and current behaviour.5  
 On the one hand, the respondents may be unable to recall past behaviour. Patterns of drug use 
and sexual practices are complex and undergo changes over time. Consequently it may be very 
difficult for respondents to recall their behaviour accurately.6 Conversely, the respondents may be able 
to remember their behaviour but be unwilling to reveal sexual and drug using practices that may be 
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stigmatised and even illegal.7 Be it deliberate or unintentional, invalid self-reported information about 
sensitive behaviour such as drug using practices and sexual behaviour can bias results. 
 Notwithstanding these concerns, a variety of approaches have shown that intravenous drug 
users often provide reasonably accurate self-reports of drug use8 and sexual behaviour.9 However, the 
research suggests that the recall period should be kept as short as possible. Consequently, during the 
interview respondents were asked to recall information primarily from two retrospective periods, 
behaviour over the previous four weeks, and over the previous three months. This design was used to 
minimize the possibility of recall bias. 
 Moreover, at first visit, clients’ upper extremities were examined for evidence of needle 
marks to determine skin condition at injecting sites. Although not presented, this information is 
recorded as a means of validating clients’ self-reported drug use.10 The data presented in this paper 
represents the total population of new clients attending the health promotion unit (n = 934) between 
May 1, 1997 and April 30, 1998. In order to examine the gender differences in self-reported behaviour 
for continuous variables, Mann Whitney tests were employed to compare groups. Categorical 
variables were analysed using chi-square with odds ratios and corresponding 95% confidence 
intervals. Percentages are based on the above returns or valid responses, adjusted for missing data. 
Missing data includes information not collected by staff at the health promotion unit, and non-
responses by clients. 
Results 
Drug use 
 Of the 934 respondents, 24.3% (n =227) were women and 75.7% (n = 707) were men. Table 1 
reveals that the first visit female clients were significantly younger than their male counterparts (p < 
0.001). Women were on average 22 years (range 15-37 years) at the point of first contact with the 
health promotion unit, while men were on average 24.2 years old (range 14-52 years). 
 There was no significant gender difference in the age of first drug use (excluding alcohol and 
tobacco) and age at first intravenous (IV) drug use. 
 All participants were asked whether they smoked an illicit drug prior to initiating intravenous 
drug use. The majority of the respondents, 86% (n = 791) reported that they had. There was no 
significant difference between the proportion of male (0.15) and female clients (0.10) who went 
straight into intravenous drug use without smoking first. However, Table 1 illustrates that female 
respondents had a significantly shorter smoking career, prior to initiating intravenous drug use, than 
their male counterparts. Moreover, the time interval between first IV drug use and presenting at the 
health promotion unit was significantly shorter for the female clients. 
 Table 2 illustrates that there was no gender difference in clients reported use of primary drug 
over the four weeks prior to contact with the health promotion unit. The majority of both male 
(92.2%) and female (90.7%) clients reported using heroin as their drug of choice. Most of these clients 
also reported IV drug use. There was no statistically significant gender difference in reported 
frequency of use of primary drug, the majority of attenders reported daily IV drug use. Despite the fact 
that female clients had significantly shorter injecting careers, the odds ratio of daily IV drug use is 
1.55 for women compared with 0.65 for men. 
Injecting practices and risk behaviour 
 Table 2 also demonstrates that there were some notable gender difference in injecting 
practices. The odds ratios illustrate that female clients were significantly more likely than their male 
counterparts to report having problems finding an injecting site. The female respondents were also 
significantly less likely to report that they injected themselves. The odds ratio for injecting self is 0.35 
for women, compared with 2.87 for men. In other words, they were more likely to need someone else 
to help with injecting. 
 With regard to injecting risk behaviour, analysis revealed that there was no significant gender 
difference in clients reporting the practices of sharing (either borrowed or lent) injecting equipment at 
some point in their IV drug using career. In terms of recent sharing behaviour, 15% of both the male 
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and female clients report lending others their injecting equipment. Although not statistically 
significant, the female clients were proportionately more likely than their male counterparts to report 
borrowing used injecting equipment. The female clients were also significantly more likely to report 
the recent sharing of injecting paraphernalia, ie. spoons and filters. 
 
Table 2: Drug use and risk behaviour by gender (categorical variable) 
Gender  Male Female Missing 
Variable OR (95% CI) OR (95% CI) observations pvalue 
Using heroin* 1.21 (0.7-2.1) 0.8 (0.5-1.1) 6 <0.472 
Injecting* 0.92 (0.5-1.6) 1.10 (0.6-1.9) 8 <0.781 
Injecting daily* 0.65 (0.4-1.0) 1.55 (0.9-2.4) 51 <0.053 
Poly-drug use* 1.09 (0.8-1.5) 0.92 (0.7-1.3) 14 <0.605 
Living with injecting drug user 0.59 (0.4-0.8) 1.69 (1.2-2.3) 11 <0.001 
Been to prison 5.87 (4.1-8.4) 0.17 (0.1-0.2) 9 <0.001 
Shared needles/syringes 0.75 (0.6-1.0) 1.34 (0.9-1.8) 19 <0.064 
Lent needles/syringes* 0.99 (0.7-1.5) 1.01 (0.7-1.5) 19 <0.968 
Borrowed needles/syringes* 0.72 (0.5-1.0) 1.38 (0.9-1.9) 23 <0.061 
Shared IV paraphernalia* 0.56 (0.4-0.8) 1.79 (1.3-2.5) 25 <0.001 
Inject self 2.87 (2.0-4.0) 0.35 (0.2-0.5) 31 <0.001 
Problem finding IV site 0.24 (0.2-0.3) 4.15 (2.9-5.9) 22 <0.001 
Multiple sexual partners1 1.35 (0.9-1.9) 0.74 (0.5-1.1) 17 <0.109 
Regular sexual partner 0.96 (0.7-1.3) 1.04 (0.8-1.4) 20 <0.813 
Injecting sexual partner 0.11 (0.1-0.2) 9.04 (5.9-13.9) 33 <0.001 
Shared needles/ 0.26 (0.2-0.4) 3.83 (2.7-5.5) 24 <0.001 
syringes with sexual partner1  
Use condoms1 1.32 (0.9-1.8) 0.76 (0.6-1.1) 17 <0.077 
*Four weeks prior to first contact 
1 Behaviour in the three months prior to contact with the health promotion unit 
Sexual risk behaviour 
 Of the male clients, 26% reported having multiple sexual partners in the three months prior to 
contact with the health promotion unit, compared with 20.7% of the female clients. Table 2 shows that 
there was no significant gender difference in clients reporting having a regular sexual partner. 
However, of those who reported having a regular sexual partner, female clients were significantly 
more likely than the male clients to have a sexual partner who is an IV drug user. Among females the 
odds of having a sexual partner who is an injecting drug user is 3.25, while among the male clients, 
the odds of having an injecting sexual partner is 0.36. 
 Women were also significantly more likely to report sharing injecting equipment (borrowing 
and lending) with their partner. Furthermore, the female clients were, as illustrated in Table 2, 
significantly more likely to report living with an injecting drug user. 
 There were no significant gender difference in reported condom use. While 67% of the male 
client reported using condoms, 60.5% of the female clients also did so. 
Health and well-being 
 Table 3 illustrates that there was no significant gender difference in reported contact with 
drug treatment services. Only 18.6% of the male clients and 19.5% of the female clients reported 
currently being in contact with other drug services in addition to the Merchant’s Quay Project. 
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 However, female clients were significantly more likely to report having been to a GP in the 
three months prior to contact with Merchant’s Quay Health Promotion Unit (OR = 2.84, 95% CI, 2.1-
3.9). This may be related to the fact that the female respondents were also significantly more likely to 
report having a medical card (70.6%). This compared with 47% of the male clients. 
 Despite the gender difference in medical contact, the male respondents were significantly 
more likely to report having had a vaccination against hepatitis B (OR = 2.15, 95% CI, 1.4-3.4). The 
vaccination was reportedly taken by 22% of the male clients, compared with only 11.4% of the female 
clients. There was no gender difference in reportedly having had an HIV test. 
 As regards health complaints, Table 3 shows that the female clients were significantly more 
likely to report having abscesses and suffering from weight loss in the three months prior to contact 
with Merchant’s Quay Health Promotion Unit. The female clients were also significantly more likely 
to report suffering from a range of mental health problems, e.g. depression, feeling unable to cope, 
feeling isolated and having suicidal tendencies. 
Discussion 
 The misuse of drug by women is not a new or even surprising phenomenon. However, with 
the possible exception of the use of prescribed psychotropic drugs and over the counter analgesics,11 
male drug users have tended to outnumber female drug users. Although this remains the case today the 
gap is steadily narrowing. 
 Many contemporary epidemiological studies demonstrate an increasing proportion of young 
women misusing a wide range of drugs.12,13 Moreover, in many country the numbers of female drug 
users is increasing at a faster rate than it is for males.14 In the context of the growth in absolute 
numbers, female drug users are still considered a minority of the total drug using population. 
However, it should be noted that there is an overall decrease in gender differences of illicit drug use 
among teenagers and young adults.15  
 It is difficult to predict a very accurate picture of the prevalence of female drug use because 
there is no way of determining the total number of women dependent on illegal drugs. In Britain, the 
Home Office figures over the last decade show a consistent figure of under 30% for notified female 
addicts.16 In Ireland, data collected by the Health Research Board for the Greater Dublin area 
illustrates that 22% of the total treatment contacts in 1995 were female,17 this increased slightly to 
28% in 199618.  
 The problem is that most of these figures are based on drug users who actually 
present for treatment, and it is generally recognised that only a small proportion of drug 
users,19 and in particular female drug users,20 are in contact with drug treatment services. 
This has been found to be the case in many international studies.20-22 Moreover, a number 
of barriers have been identified to women entering treatment. These include women’s lack of 
economic resources,23 childcare concerns, 24 and the perceived insensitivity of treatment setting to 
women’s problems.25  
Table 3: Health and medical contact by gender 
Gender  Male Female 
Variable OR (95% CI) (OR (95% CI) missing pvalue 
     observations 
In treatment 0.94 (0.6-1.4) 1.06 (0.7-1.6) 2 <0.759 
Medical card 0.37 (0.3-0.5) 2.69 (1.9-3.7) 20 <0.001 
Contact with GP1 035 (0.3-0.5) 2.84 (2.1-3.9) 19 <0.001 
HIV test1 0.99 (0.7-1.3) 1.01 (0.7-1.4) 34 <0.947 
Vaccination Hep B1 2.15 (1.4-3.4) 0.46 (0.3-0.7) 33 <0.001 
Abscesses1 0.56 (0.4-0.8) 1.78 (1.2-2.6) 58 <0.012 
Weight loss1 0.72 (0.5-1.0) 1.38 (0.9-1.9) 56 <0.055 
Insomnia1 1.02 (0.7-1.4) 0.98 (0.7-1.4) 52 <0.917 
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Thrombosis1 0.73 (0.5-1.1) 1.37 (0.9-1.9) 73 <0.097 
Depression1 0.42 (0.3-0.6) 2.36 (1.6-3.4) 52 <0.001 
Anxiety1 0.76 (0.5-1.0) 1.32 (0.9-1.8) 62 <0.078 
Unable to cope1 0.57 (0.4-0.8) 1.75 (1.3-2.4) 58 <0.001 
Isolated1 0.66 (0.5-0.9) 1.52 (1.1-2.1) 61 <0.008 
Suicidal1 0.49 (0.4-0.7) 2.01 (1.4-2.8) 64 <0.001 
1 This refers to the three months prior to contact 
 One Irish study has, however, attempted to estimate the prevalence of opiate use in Dublin. 
Comiskey26 employed the capture-recapture methodology using data from three different sources: the 
central patient methadone treatment list, the hospital inpatients enquiry database and police arrests. 
The estimated total number of opiate users was put at 13,460 and the ratio of male to female opiate 
users was estimated to be 3:1. The gender ratio of first time attenders at the Merchant’s Quay Health 
Promotion Unit is the same. 
 This indicates that the health promotion unit does not deter new female presenters. This is 
further supported by the fact that the time interval between first use of drugs and first presentation at 
the service was significantly shorter for women. If women were deterred from attending the unit, then 
the delay between onset of drug use and first presentation should be greater. 
 This early presentation by female clients may in part be due to the fact that the rate of 
physical and mental deterioration is, as other research suggests, more rapid among injecting women, 
so they quickly reach the state of requiring treatment.22, 27 There is some evidence to suggest that this 
may be the case among the women attending the Merchant’s Quay Health Promotion Unit. 
 Firstly, although there was no significant gender difference in drug use, the female clients in 
this study, despite their significantly shorter injecting careers, were proportionately more likely to 
inject their primary drug daily. Moreover, the women were significantly more likely to report 
suffering from injecting related problems such as difficulty finding IV sites, having abscesses and 
thromboses. 
 Secondly, the women were more likely than their male counterparts to report suffering from 
mental health problems, such as depression, anxiety, feeling unable to cope and feeling isolated. This 
is supported by international research which has found that women drug users complain of a range of 
medical and psychological problems more often, and to a greater extent than do their male counter- 
parts.28 Indeed it is often medical complaints that precipitate women’s entrance into drug treatment.29  
 However, one cannot ignore the possibility that, as other research indicates, women are 
simply more likely to admit to having health problems and are more likely to attend medical services 
than men.30 This is highlighted by the fact that the female drug users in this study were significantly 
more likely than their male counterparts to report having had recent contact with a GP. 
 This study also shows important gender differences in terms of the extent of personal 
involvement with other drug users. The female attenders were significantly more likely to be involved 
in a sexual relationship with an injecting drug user. These findings are consistent with those of studies 
in both the UK16 and the US.22 Moreover, it was also found that women were significantly more likely 
to report living with an injecting drug user. Research in the UK has found that living with an injecting 
drug user is related to the sharing of injecting equipment and paraphernalia, primarily because it 
creates a social environment that leads to sharing.31  
 The greater personal involvement of women with other drug users highlighted in this study 
could have considerable impact on prognosis and clinical intervention, by simultaneously depriving 
them of protective factors and exposing them to high risk factors.16 This in turn has implications for 
service providers. However, it has been shown that the availability of social support is a predicator of 
abstinence and good treatment outcomes.32  
 The fact that women are presenting at an earlier stage in their drug taking cycle poses a 
particular challenge to drug treatment services to design programmes that engage rather than alienate 
women. Adopting a client-centred approach is essential in this regard and should be complemented by 
the provision of a woman-only service. When we consider the dual factors of female drug users 
presenting younger and at an earlier stage, it creates a hopeful picture. 
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 Although there is no evidence to date to substantiate claims that interventions with younger 
drug users are necessarily more successful or effective, there are certain implications which might 
have positive outcomes for treatment initiatives. These outcomes relate more specifically to 
influencing drug usage patterns, thereby reducing risk behaviour; persuading young drug users to 
engage in drug treatment services and progressing young drug users incrementally towards a 
consideration of a drug free lifestyle. 
 To conclude, this research has illustrated that the question of number is really a non-issue. 
What is important is the fact that young women drug users exist, and that they are more likely than 
their male counterparts to engage in risk behaviour which has a detrimental effect on their mental and 
physical health. 
 However, the findings of this study have illustrated that female drug users are more willing to 
acknowledge these difficulties and seek help. The challenge is to harness their needs or requests for 
assistance into non-judgemental client-centred services which not only engage them in their crisis but 
also sustains their participation across a range of treatment options. This will provide the opportunity 
to build sequentially on their progress and development which may involve a progression from chaotic 
drug use to an independent, sustainable drug-free lifestyle. 
Acknowledgements 
 The authors are indebted to the clients of the Merchant’s Quay Project without whom this 
research would have been impossible. We are grateful to the staff of the health promotion unit for 
enthusiastically cooperating with the research. We are also very grateful for the technical assistance 
provided by Marie Lawless. The Merchant’s Quay project is a voluntary organisation funded in part 
by the Department of Justice, EHB, FAS, Inner City Trust, the Franciscan community and various 
private grants and donators. 
Reference 
1. Single E. Defining harm reduction. Drug Alcohol Rev 1995; 14: 287-90. 
2. Newcombe R. The reduction of drug related harm: a conceptual framework for theory, 
practice and research. In: O’Hare P, Newcombe R, Matthews A, Buning U, Drucker U (eds). 
The reduction in drug-related harm. London: Routledge, 1992. 
3. O’Connor J, Stafford-Johnson S, Kelly M. A review of the characteristics and treatment 
progress of 45 pregnant opiate addicts attending the Irish National Drug Advisory and 
Treatment Centre over a two year period. Irish J Med Sci 1988; 157 (5): 146-9 
4. Keenan E, Dorman A, O’Connor J. Six year follow-up of 45 pregnant opiate addicts. Irish J 
Med Sci 1993; 162 (7): 252-5 
5. Harrell A. Validation of self-report: the research record. In: Rouse B, Kozel N, Richards L 
(eds). Self-report methods of estimating drug use: meeting current challenges to validity. 
NIDA, Rockville 1985; 12-21 
6. Bradburn N, Rips L, Shevell S. Answering autobiographical questions: the impact of memory 
and inference on survey. Science 1987; 236: 157-61 
7. Siegel K, Bauman L. Methodological issues in AIDS-related research. In: Feldman D, 
Johnson T (eds). The social dimensions of AIDS: methods and theory. New York: Praeger 
1986; 15-39. 
8. McElrath K, Chitwood D, Griffin D, Comerford M. The consistency of self-reported HIV risk 
behaviour among injecting drug users. Am J Public Health 1994; 84 (12): 1965-70. 
9. Kleun J, Schwebke J, Holmes K. The validity of injecting drug users self-report about 
sexually transmitted disease: a comparison of survey and serological data. Addiction 1994; 
88: 673-80. 
8 
10. Anthony J et al. Self-report interview data for a study of HIV-1 infection among intravenous 
drug users: description of methods and preliminary evidence on validity. J Drug Issues 1991; 
21: 739-57. 
11. Ettorre F. Women and substance use. London: Macmillan, 1992. 
12. Ghodse A et al. The effect of maternal narcotics addiction on the new born infant. Psychol 
Med 1977; 667-75 
13. Parker H, Measham F. Pick ‘n’ mix: changing patterns of illicit drug use amongst 1990s 
adolescents. Drugs: Education, Prevention and Policy 1994; 1 (1) 5-13. 
14. Sanchez J, Johnson B. Women and the drugs-crime connection: crime rates among drug 
abusing women at Riker Island. J Psychoactive Drugs 1987; 19: 205-16. 
15. Hser Y, Anglin d, McGlothlin W. Sex differences in addict careers: 1. Initiation of use. Am J 
Drug Alcohol Abuse 1987; 13 (1,2): 33-57. 
16. Gossop M, Griffiths P, Strang J. Sex differences in patterns of drug taking behaviour. Br. J 
Psychiat 1994; 164: 101-4. 
17. O’Higgins K, Duff P. Treated drug misuse in Ireland: first national report 1995. Dublin: 
Health Research Board, 1997. 
18. Moran R, O’Brien M, and Duff P. Treated drug misuse in Ireland: national report 1996. 
Dublin: Health Research Board, 1997. 
19. Hartnoll R, Mitcheson M, Lewis R, Bryer S. Estimates of the prevalence of opioid 
dependence. Lancet 1985; 203-5. 
20. Berridge V. Drugs research and policy in Britain. Avebury, Aldershot 1990. 
21. Paone U, Des Jarlais D, Gangloff R, Milliken J, Friedman S. Syringe exchanges: HIV 
prevention, key findings and future direction, Int J Addict 1995; 30 (420): 1647-83. 
22. Anglin M, Hser Y, Booth M. Sex differences in addict careers. 4. Treatment. Am J Drug 
Alcohol Abuse 1987; 13: 253-80. 
23. Hodgins D, El-Guebaly N, Addington J. Treatment of substance abusers: single or mixed 
gender programs? Addiction 1997; 92 (7): 805-12. 
24. Cuskey W. Female addiction: a review of the literature. Focus on women: J Addict Health 
1982; 13 (1): 3-33. 
25. Reed B. Developing women-sensitive drug dependence treatment services: why so difficult? J 
Psychoactive Drugs1987; 19 (2): 151-64. 
26. Comiskey C. Estimating the prevalence of opiate use in Dublin, Ireland during 1996. 
Tallaght: Institution of Technology, 1998. 
27. Moise R, Reed B, and Ryan V. Issues in the treatment of heroin-addicted women: a 
comparison of men and women entering two types of drug abuse programs. Int J Addict 
1982;17 (1): 109-39. 
28. Mondararo J. Chemically dependent women: assessment and treatment. Massachucsette: 
Lexington Books, Lexington, 1989. 
29. Rosenbaum M, Murphy S. Not the picture of health: women on methadone. J Psychoative 
Drugs 1987; 19 (2): 217-26. 
30. Cooperstock R. Sex differences in the use of mood-altering drugs: an explanatory model. J 
Health Social Behav 1971; 12: 238-44 
31. Donoghoe M, Dolan K, Stimson G. Lifestyle factors and social circumstances of syringe 
sharing in injection drug users. Br J Add 1992; 87: 993-1003. 
32. Gossop M et al. Factors predicting outcome among opiate addicts after treatment. Br J Clin 
Psy 1990; 29: 209-16. 
 
